Stephanie M. Pryor

Associate

紐約 + 1.212.326.3416

Stephanie Pryor's practice focuses on corporate criminal matters and government investigations. She defends clients facing U.S. Department of Justice (DOJ), Internal Revenue Service (IRS), and Securities and Exchange Commission (SEC) actions. She has assisted with investigations and litigation involving allegations of health care fraud, tax evasion, foreign bribery, and money laundering.

In addition to litigating, Stephanie advises foreign and domestic financial institutions on matters involving federal and state financial regulations. Her experience centers largely on the U.S. anti-money laundering (AML) framework, including compliance with the Bank Secrecy Act (BSA) and its implementing regulations. She is the associate manager of the Firm's working group on anti-money laundering and sanctions and devotes significant attention to monitoring U.S. and international developments in these areas.

Stephanie maintains an active pro bono practice, focusing on sensitive immigration matters and representing clients in family and immigration courts.

Prior to attending law school, Stephanie's career in college athletics included working for both of her alma maters, NYU and Rutgers. During law school, she interned with in-house counsel at Major League Baseball and volunteers annually for the Heisman Trophy Trust.

執業經驗

  • Asia-based telecom company responds to UN corruption investigationJones Day represents an Asia-based telecommunications company in a corruption investigation by a UN agency.
  • CEO defends grand jury investigation relating to tax affairsJones Day represents a CEO in a federal grand jury investigation conducted by the U.S. Department of Justice's Tax Division regarding the CEO's tax affairs.
  • Pharmaceutical company defends putative securities fraud class actionJones Day represents a pharmaceutical company, along with current and former officers, in a putative securities fraud class action arising from announcements the company made related to three different drugs in development or on the market, which the plaintiff claims together caused the company's stock to drop 40 percent.